Portugal’s EU JCA alignment map shows that outcome scoping carries the largest methodology gap. https://www.mattheneus.com/editorial/portugal-eu-jca-methodology-alignment-outcome-scoping-gaps-2026-10-07 #HTA #EvidenceSynthesis #RegulatoryAffairs

EU selects its first two medical devices for joint clinical assessment. https://www.mattheneus.com/editorial/european-commission-first-medical-device-jca-sapien-m3-highlife-mitral-valves-2026-10-06 #HTA #RegulatoryAffairs #HealthEconomics

WHO updates pre-eclampsia evidence across magnesium sulfate, aspirin and calcium, sharpening priorities for maternal health. https://www.mattheneus.com/editorial/who-pre-eclampsia-fact-sheet-magnesium-aspirin-calcium-evidence-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics

Arm-wise target matching is now available for anchored MAIC in AbangeLabs HTA Studio. https://www.mattheneus.com/editorial/abangelabs-hta-studio-anchored-maic-weighting-strategy-arm-wise-target-matching-2026-10-08 #HTA #MAIC #EvidenceSynthesis

A time-aligned network of 24 studies sharpens comparative treatment evidence in prurigo nodularis. https://www.mattheneus.com/editorial/prurigo-nodularis-time-aligned-treatment-network-2026-10-07 #HTA #NMA #EvidenceSynthesis

Composite stimulation patterns sharpen evidence on postoperative recovery. https://www.mattheneus.com/editorial/pubmed-transcutaneous-electrical-acupoint-stimulation-postoperative-recovery-composite-pattern-2026-10-07 #HTA #EvidenceSynthesis

WHO’s six-month gateway reframes when adolescent obesity pharmacotherapy enters a multimodal pathway. https://www.mattheneus.com/editorial/who-adolescent-obesity-guideline-six-month-multimodal-pharmacotherapy-pathway-2026-10-07 #HTA #Pharma #RegulatoryAffairs

Korjuny’s UK approval for malignant ascites puts randomised drainage-control evidence in focus. https://www.mattheneus.com/editorial/mhra-korjuny-catumaxomab-malignant-ascites-randomised-paracentesis-2026-10-02 #HTA #RegulatoryAffairs #EvidenceSynthesis

Daily sedation interruption may shorten ventilation and lower mortality, according to a Cochrane review. https://www.mattheneus.com/editorial/cochrane-daily-sedation-interruption-ventilation-mortality-randomised-review-2026-10-07 #HTA #EvidenceSynthesis #HealthEconomics

A $5.85M federal challenge tests automated evidence synthesis against hidden benchmarks for reproducibility. https://www.mattheneus.com/editorial/ahrq-clinical-evidence-synthesis-hidden-benchmark-reproducibility-2026-10-07 #HTA #EvidenceSynthesis #RegulatoryAffairs

The UK’s 44-point healthcare AI plan makes evidence strategy central: staged access will depend on credible economic appraisal. #HTA #HealthEconomics #RegulatoryAffairs https://www.mattheneus.com/editorial/uk-healthcare-artificial-intelligence-staged-access-economic-appraisal-2026-10-06

Spain’s patient-involvement protocol turns recruitment and feedback into auditable HTA practice. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/spain-redets-patient-involvement-monitoring-protocol-49-reports-2026-10-05

AHRQ is offering 1.8 million for research on healthcare competition and patient choice, putting evidence behind market reform. https://www.mattheneus.com/editorial/ahrq-healthcare-choice-competition-challenge-market-reform-evidence-2026-10-06 #HTA #HealthEconomics #RWE

EMA has opened an IRIS route for EU-M4all eligibility requests, sharpening how disease-burden evidence enters global-medicine pathways. https://www.mattheneus.com/editorial/ema-eu-m4all-iris-eligibility-disease-burden-evidence-route-2026-08-18 #HTA #RegulatoryAffairs #EvidenceSynthesis

The Health Economics Methods Advisory (#HEMA) today released a Draft Report on how HTA bodies can evaluate, present, and communicate uncertainty in #healtheconomic evaluations. #hta #populationhealth

Now accepting public comments until Nov 2. Read more: shorturl.at/mOe0F

Germany's machine-readable benefit decisions create a reproducible evidence baseline. https://www.mattheneus.com/editorial/g-ba-machine-readable-benefit-decisions-xml-evidence-baseline-2026-10-07 #HTA #RegulatoryAffairs #EvidenceSynthesis

Two-stage economic evidence reviews can reduce HTA rework. https://www.mattheneus.com/editorial/pharmacoeconomics-systematic-health-economic-evaluation-reviews-two-stage-hta-2026-10-06 #HTA #HealthEconomics #Pharma

Bone-healing NMA separates modality effects from functional recovery. https://www.mattheneus.com/editorial/pubmed-electrical-stimulation-bone-healing-network-meta-analysis-modality-ranking-2026-10-07 #HTA #NMA #EvidenceSynthesis

Risk misclassification can reshape the value case for risk-stratified breast screening. https://www.mattheneus.com/editorial/risk-stratified-breast-screening-misclassification-capacity-cost-effectiveness-2026-10-01 #HTA #HealthEconomics #EvidenceSynthesis

A €607 annual price threshold sharpens the value case for empagliflozin after myocardial infarction. https://www.mattheneus.com/editorial/pubmed-empagliflozin-post-mi-heart-failure-risk-price-threshold-2026-10-05 #HTA #HealthEconomics #Pharma